MT-1 (Melanotan I) Research: MC1R-Selective Melanocortin Pharmacology

MT-1, formally known as Melanotan I or Afamelanotide, is a synthetic linear tridecapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Developed in the 1980s at the University of Arizona through structure-activity relationship optimisation of alpha-MSH, MT-1 incorporates two key substitutions from the native sequence — norleucine at position 4 and D-phenylalanine at position 7 — that substantially improve receptor binding affinity, metabolic stability, and research utility.

Molecular Structure and Key Modifications

Native alpha-MSH (13 amino acids: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) has a plasma half-life of approximately 30 minutes, limiting its use as a research tool for sustained receptor activation studies.

MT-1 addresses this through two substitutions:

Nle4 (norleucine at position 4). Native alpha-MSH contains methionine at position 4, which is susceptible to oxidation — particularly in cell culture media containing oxygen. Norleucine is structurally analogous to methionine (same chain length) but contains a simple n-butyl side chain rather than a thioether, making it completely resistant to oxidative degradation. This substitution eliminates a major instability without affecting receptor binding.

D-Phe7 (D-phenylalanine at position 7). The L-Phe7 in native alpha-MSH is the primary site of endopeptidase attack. Substituting D-phenylalanine creates a stereochemical mismatch that most L-specific endopeptidases cannot cleave. This single substitution extends the plasma half-life substantially and improves potency by approximately 1000-fold compared to native alpha-MSH.

MC1R Pharmacology

MC1R is a Gs-coupled GPCR expressed predominantly on melanocytes, melanoma cells, macrophages, dendritic cells, and natural killer cells. MT-1's selectivity for MC1R versus other MCR subtypes (MC3R, MC4R, MC5R) makes it the preferred research tool when MC1R-specific effects need to be isolated.

MC1R activation by MT-1 drives the following signalling cascade in melanocyte research models: Gs protein activation raises adenylyl cyclase activity, increasing intracellular cAMP. PKA activation follows, phosphorylating CREB transcription factor. Phospho-CREB drives transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte gene expression. MITF in turn upregulates tyrosinase (rate-limiting enzyme of melanin synthesis), TYRP1, and DCT — producing increased eumelanin synthesis and melanosome maturation.

MT-1 vs MT-2 vs PT-141: Research Tool Selection

Understanding the structural and pharmacological differences between these three melanocortin research compounds is essential for experimental design.

Use MT-1 for MC1R-specific research: melanogenesis studies, UV response, photoprotection mechanisms, and MC1R receptor binding assays. Use MT-2 for pan-melanocortin receptor studies or when MC4R and MC1R co-activation is desired. Use PT-141 for central MC4R biology and CNS melanocortin research.

Afamelanotide Clinical Research Context

MT-1 is identical in sequence to Afamelanotide, which has been studied in multiple clinical trials for erythropoietic protoporphyria (EPP) — a condition where MC1R-driven melanin production provides photoprotection. Published Phase 3 trial data provides extensive pharmacokinetic and receptor pharmacology data that supports MT-1's use as a laboratory research tool. The clinical development of Afamelanotide has produced one of the more robust published datasets for any synthetic melanocortin peptide.

Published Research References

For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.

Related research peptides: MT-2 (Melanotan II) | PT-141 (Bremelanotide) | Kisspeptin-10
View MT-1 product and buy →

MC1R in Immunology: Beyond Pigmentation

MC1R research has expanded substantially beyond melanocyte pigmentation to immunological biology. MC1R is expressed on macrophages, dendritic cells, natural killer cells, and T lymphocytes — immune cells with no pigmentation function. In these immune cell contexts, MC1R activation by alpha-MSH (or MT-1 as the stable research analogue) drives anti-inflammatory signalling:

Macrophage MC1R: Activation reduces LPS-stimulated TNF-alpha, IL-6, and IL-12 production through cAMP/PKA-mediated suppression of NFkB activity. This has been studied in RAW264.7 cells and primary peritoneal macrophages using MT-1 as the stimulating compound at concentrations that saturate MC1R without activating MC3R or MC5R (using MC1R-selective concentrations established from binding assays).

Dendritic cell MC1R: Published research has examined alpha-MSH in the context of dendritic cell maturation and T cell priming — specifically whether MC1R activation shifts dendritic cells toward a tolerogenic phenotype that promotes regulatory T cell differentiation rather than effector T cell activation. MT-1 is the preferred tool for this research due to MC1R selectivity.

Keratinocyte MC1R: Keratinocytes (the dominant skin epithelial cell type) express MC1R and respond to alpha-MSH/MT-1 with increased melanocyte-stimulating paracrine signalling and with direct anti-inflammatory effects including IL-10 production and prostaglandin E2 suppression.

Afamelanotide Clinical Research Context

MT-1 is identical to Afamelanotide, which has published Phase 3 clinical trial data in erythropoietic protoporphyria (EPP). EPP is a rare disorder where mutations in ferrochelatase impair haem synthesis, causing porphyrin accumulation and extreme photosensitivity — even brief sun exposure causes burning pain. Afamelanotide's MC1R-mediated melanin induction provides photoprotection without sun exposure, reducing the reactive oxygen species generated by porphyrin photoactivation.

This published clinical dataset (Langendonk et al., NEJM 2015) provides pharmacokinetic and pharmacodynamic reference data for MT-1 in humans: plasma half-life approximately 15 hours after subcutaneous administration (due to prolonged release from implants), peak melanogenic effect at 7-10 days, and MC1R-mediated signalling characterised through skin reflectance and biopsy endpoints. This clinical pharmacology data contextualises laboratory research using MT-1 for MC1R receptor studies.

Frequently Asked Questions

How does MT-1 differ from self-tanning products and what does this mean for research?
Self-tanning products (containing dihydroxyacetone, DHA) produce skin darkening through non-enzymatic chemical reaction with skin proteins — they do not activate MC1R or melanogenesis and produce a brown coloration from protein modification rather than melanin. MT-1 activates MC1R to stimulate the actual melanin biosynthesis pathway — producing eumelanin in melanosomes that is biologically authentic photoprotective pigment. For research examining UV response biology, MC1R-driven melanogenesis (MT-1 research tool), and actual melanin synthesis, MT-1 is the relevant research tool rather than any DHA-based approach.

What is the connection between MC1R variants and melanoma risk?
Human MC1R has multiple common polymorphic variants (particularly in red-haired, fair-skinned populations) that reduce MC1R signalling efficiency. These reduced-function MC1R variants are associated with impaired melanogenic response to UV, reduced photoprotection, and increased melanoma risk in epidemiological studies. MT-1 research examining MC1R variant pharmacology — comparing dose-response curves for MC1R activation between reference and variant receptor sequences — contributes to understanding the molecular basis for the clinical correlation between MC1R variants and melanoma susceptibility.

Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide